342 related articles for article (PubMed ID: 10796790)
21. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia.
Grasso M; Montesano A; Buonaguidi A; Castelli M; Lania C; Rigatti P; Rocco F; Cesana BM; Borghi C
Arch Esp Urol; 1995; 48(1):97-103. PubMed ID: 7537488
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Ye Z; Huang J; Zhou L; Chen S; Wang Z; Ma L; Wang D; Wang G; Wang S; Liang C; Qiu S; Gu X; Liu J; Weng Z; Wu C; Wei Q; Xie L; Wu W; Cheng Y; Hu J; Wang Z; Zeng X
Urology; 2019 Jul; 129():172-179. PubMed ID: 30880074
[TBL] [Abstract][Full Text] [Related]
23. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
[TBL] [Abstract][Full Text] [Related]
24. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine.
Ooi SL; Pak SC
J Altern Complement Med; 2017 Aug; 23(8):599-606. PubMed ID: 28436684
[TBL] [Abstract][Full Text] [Related]
25. Comparison of
Cai T; Cui Y; Yu S; Li Q; Zhou Z; Gao Z
Am J Mens Health; 2020; 14(2):1557988320905407. PubMed ID: 32274957
[TBL] [Abstract][Full Text] [Related]
26. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.
Cicero AFG; Allkanjari O; Busetto GM; Cai T; Larganà G; Magri V; Perletti G; Robustelli Della Cuna FS; Russo GI; Stamatiou K; Trinchieri A; Vitalone A
Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577095
[TBL] [Abstract][Full Text] [Related]
27. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial].
Glemain P; Coulange C; Billebaud T; Gattegno B; Muszynski R; Loeb G;
Prog Urol; 2002 Jun; 12(3):395-403; discussion 404. PubMed ID: 12189745
[TBL] [Abstract][Full Text] [Related]
28. The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens.
Giannakopoulos X; Baltogiannis D; Giannakis D; Tasos A; Sofikitis N; Charalabopoulos K; Evangelou A
Adv Ther; 2002; 19(6):285-96. PubMed ID: 12665049
[TBL] [Abstract][Full Text] [Related]
29. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia.
MacDonald R; Ishani A; Rutks I; Wilt TJ
BJU Int; 2000 May; 85(7):836-41. PubMed ID: 10792162
[TBL] [Abstract][Full Text] [Related]
31. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis.
Ishani A; MacDonald R; Nelson D; Rutks I; Wilt TJ
Am J Med; 2000 Dec; 109(8):654-64. PubMed ID: 11099686
[TBL] [Abstract][Full Text] [Related]
32. [Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms].
Amdii RE; Al' Shukri AS
Urologiia; 2018 May; (2):114-120. PubMed ID: 29901305
[TBL] [Abstract][Full Text] [Related]
33. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials.
Russo GI; Scandura C; Di Mauro M; Cacciamani G; Albersen M; Hatzichristodoulou G; Fode M; Capogrosso P; Cimino S; Marcelissen T; Cornu JN; Gacci M; Minervini A; Cocci A;
Eur Urol Focus; 2021 Mar; 7(2):420-431. PubMed ID: 31952967
[TBL] [Abstract][Full Text] [Related]
34. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
[TBL] [Abstract][Full Text] [Related]
35. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
Buck AC
J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
[TBL] [Abstract][Full Text] [Related]
36. Serenoa repens (saw palmetto): a systematic review of adverse events.
Agbabiaka TB; Pittler MH; Wider B; Ernst E
Drug Saf; 2009; 32(8):637-47. PubMed ID: 19591529
[TBL] [Abstract][Full Text] [Related]
37. Hexanic Extract of Serenoa repens (Permixon
Blair HA
Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
[TBL] [Abstract][Full Text] [Related]
38.
Franco JVA; Trivisonno LF; Sgarbossa N; Alvez GA; Fieiras C; Escobar Liquitay CM; Jung JH
World J Mens Health; 2024 Jan; ():. PubMed ID: 38164033
[TBL] [Abstract][Full Text] [Related]
39. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
[TBL] [Abstract][Full Text] [Related]
40. beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.
Wilt TJ; MacDonald R; Ishani A
BJU Int; 1999 Jun; 83(9):976-83. PubMed ID: 10368239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
